Cubist Systematic Strategies, LLC - RIGEL PHARMACEUTICALS INC ownership

RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 163 filers reported holding RIGEL PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.95 and the average weighting 0.1%.

Quarter-by-quarter ownership
Cubist Systematic Strategies, LLC ownership history of RIGEL PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$130,600
-33.1%
101,240
-31.6%
0.00%0.0%
Q1 2023$195,361
-52.2%
148,001
-45.7%
0.00%
-50.0%
Q4 2022$408,708
+104.4%
272,472
+60.6%
0.00%
+100.0%
Q3 2022$200,000
+138.1%
169,703
+127.3%
0.00%0.0%
Q2 2022$84,000
+52.7%
74,675
+308.2%
0.00%
Q1 2022$55,000
-1.8%
18,295
-12.9%
0.00%
-100.0%
Q4 2021$56,000
+133.3%
21,000
+217.6%
0.00%
Q3 2021$24,000
-80.6%
6,612
-81.7%
0.00%
-100.0%
Q1 2021$124,000
+33.3%
36,148
+36.6%
0.00%
+100.0%
Q4 2020$93,000
-31.1%
26,471
-53.0%
0.00%
-50.0%
Q3 2020$135,000
+92.9%
56,292
+51.4%
0.00%
+100.0%
Q3 2019$70,000
+118.8%
37,193
+206.9%
0.00%0.0%
Q2 2019$32,000
-83.2%
12,117
-83.6%
0.00%
-83.3%
Q1 2019$190,000
-2.1%
73,986
-12.5%
0.01%
-33.3%
Q4 2018$194,000
+185.3%
84,520
+299.5%
0.01%
+125.0%
Q3 2018$68,000
-60.2%
21,159
-65.1%
0.00%
-55.6%
Q2 2018$171,000
+140.8%
60,559
+199.9%
0.01%
+125.0%
Q1 2018$71,000
-24.5%
20,193
-45.4%
0.00%
-20.0%
Q3 2017$94,000
+91.8%
36,986
+79.8%
0.01%
+25.0%
Q4 2016$49,000
-58.1%
20,571
-35.7%
0.00%
-50.0%
Q3 2016$117,000
+317.9%
32,014
+137.1%
0.01%
+300.0%
Q1 2016$28,000
-36.4%
13,503
-25.0%
0.00%0.0%
Q3 2015$44,000
-44.3%
18,007
-18.7%
0.00%
-50.0%
Q1 2015$79,00022,1560.00%
Other shareholders
RIGEL PHARMACEUTICALS INC shareholders Q2 2021
NameSharesValueWeighting ↓
DAFNA Capital Management LLC 1,847,087$4,119,0003.26%
Sio Capital Management, LLC 1,333,696$2,974,0001.52%
Boxer Capital, LLC 700,000$1,561,0001.38%
Palo Alto Investors LP 5,386,534$12,012,0000.91%
ACUTA CAPITAL PARTNERS, LLC 747,748$1,667,0000.80%
SENZAR ASSET MANAGEMENT, LLC 1,443,003$3,217,897,0000.70%
Ghost Tree Capital, LLC 800,000$1,784,0000.52%
NEA Management Company, LLC 3,243,150$7,232,0000.38%
Rhenman & Partners Asset Management AB 850,000$1,896,0000.34%
Rock Springs Capital Management LP 1,750,000$3,903,0000.29%
View complete list of RIGEL PHARMACEUTICALS INC shareholders